FDA warns of compounded drug recall by Texas firm

(AP)—The Food and Drug Administration is warning doctors not to use compounded drugs from a Texas specialty pharmacy due to risks of contamination.

The agency says FDA inspectors recently uncovered unsanitary conditions at Unique Pharmaceuticals' plant in Temple, Texas. The inspections revealed production problems in several lots of drugs that were supposed to be sterile.

The company is now recalling all non-expired sterile products distributed across the U.S., including a fluid used to clear mucus from the airways of patients with respiratory conditions.

The FDA said in a statement it is not aware of any illnesses linked to the products.

Unique Pharmaceuticals is a compounding pharmacy, which means it produces customized medications to fill specifications made by doctors.

Compounding pharmacy operations have been repeatedly linked to contamination problems for decades.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Indianapolis pharmacy recalls compounded drugs

Apr 23, 2013

(AP)—A pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential safety problems during an inspection.

Fla. compounding pharmacy recalls sterile drugs

Apr 21, 2013

A Florida-based compounding pharmacy is voluntarily recalling all lots of its sterile non-expired drug products sold nationwide over concerns the products are not sterile and may contain bacteria.

FDA: Georgia pharmacy recalling all sterile drugs

Mar 21, 2013

(AP)—The Food and Drug Administration says a Georgia compounding pharmacy that distributed a drug linked to eye infections is now recalling all of its injectable medicines following a federal inspection.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

16 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments